Table 1. Subject characteristics.
| Control | CVE | CKD5HD | CKD5HD/CVE | |
|---|---|---|---|---|
| (n = 9) | (n = 11) | (n = 10) | (n = 10) | |
| Age (years) | 63.1 ± 2.4 | 65.7 ± 3.4 | 64.8 ± 4.3 | 72.3 ± 2.1 |
| Gender (M/F) | 5/4 | 6/5 | 5/5 | 5/5 |
| Dialysis vintage | NA | NA | 61.7 (23.9–210.5) | 43.2 (12.8–98.9) |
| (months) | ||||
| BUN (mg/dl) | 15.42 | 18.44 | 63.27*** Ɩ °°° | 47.56*** Ɩ °°° |
| (11.21–21.96) | (11.21–28.50) | (42.99–96.73) | (23.83–60.28) | |
| Creatinine (mg/dl) | 0.89 ± 0.04 | 0.88 ± 0.05 | 9.53 ± 0.69*** Ɩ °°° | 7.95 ± 0.71*** Ɩ °°° |
| Leukocytes(/μl) | 5841 ± 285 | 6008 ± 490 | 5473 ± 538 | 5599 ± 398 |
| Monocytes (%) | 8.6 ± 0.6 | 8.9 ± 0.6 | 10.1 ± 0.8 | 8.8 ± 0.8 |
| Lymphocytes (%) | 29.4 ± 2.6 | 29.0 ± 2.6 | 29.1 ± 2.7 | 22.5 ± 1.7 |
| Granulocytes (%) | 62.0 ± 2.6 | 62.2 ± 2.3 | 60.1 ± 3.2 | 64.6 ± 3.8 |
| Total protein (g/dl) | 7.4 ± 0.1 | 7.5 ± 0.2 | 6.8 ± 0.1*** Ɩ ° | 6.9 ± 0.2* Ɩ ° |
| Albumin (mg/dl) | 4.5 ± 0.1 | 4.6 ± 0.1 | 4.1 ± 0.1*** Ɩ °° | 4.0 ± 0.1** Ɩ °° |
| CRP (mg/dl) | 0.1 (0.05–0.1) | 0.1 (0.05–1.1) | 0.7 (0.2–1.6)*** Ɩ ° | 0.5 (0.1–1.8)*** Ɩ ° |
| GFR (ml/min/1.73m2; CKD-epi) | 82.1 ± 4.4 | 82.6 ± 3.9 | NA | NA |
| Aspirin use | 2 | 10** | 1 °°° | 5 |
| Statin use | 2 | 8* | 4 | 9** |
Values reported are mean ± SEM when normally distributed, otherwise median and range (in parentheses) are given.
*** p < 0.001
** p < 0.01
* p < 0.05 vs. control
°°° p < 0.001
°° p < 0.01
° p < 0.05 vs. CVE
No significant differences were found between CKD5HD and CKD5HD/CVE.
Abbreviations: CVE: patients with eGFR > 60 mL/min/1.73m² and a history of cardiovascular event; CKD5HD: hemodialysis patients without previous cardiovascular event; CKD5HD/CVE: hemodialysis patients with a previous cardiovascular event; CRP: C-reactive protein; GFR: glomerular filtration rate; NA: not applicable